Anika Therapeutics Inc logo

ANIK - Anika Therapeutics Inc Share Price

$38.96 -0.3  -0.7%

Last Trade - 22/01/21

Sector
Healthcare
Size
Mid Cap
Market Cap £406.1m
Enterprise Value £333.6m
Revenue £92.9m
Position in Universe 3271st / 6626
Bullish
Bearish
Unlock ANIK Revenue
Momentum
Relative Strength (%)
1m -14.9%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -17.4%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
103.2
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
105.6 93.0 103.4 113.4 105.6 114.6 131.3 150.3 +1.7%
+82.4 -20.0 +7.3 -9.0 -34.9 +48.4
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, AnikaTherapeutics Inc revenues increased 15% to $97.8M. Net losstotaled $8.3M vs. income of $23.1M. Revenues reflect Othersegment increase of 14% to $5.4M, United States segmentincrease of 17% to $77.8M, Other. segment increase of 83%to $8.8M. Net loss reflects Selling, general &administrative - Bala increase from $19.2M to $42.1M(expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ANIK Revenue Unlock ANIK Revenue

Net Income

ANIK Net Income Unlock ANIK Revenue

Normalised EPS

ANIK Normalised EPS Unlock ANIK Revenue

PE Ratio Range

ANIK PE Ratio Range Unlock ANIK Revenue

Dividend Yield Range

ANIK Dividend Yield Range Unlock ANIK Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ANIK EPS Forecasts Unlock ANIK Revenue
Profile Summary

Anika Therapeutics, Inc. is a joint preservation company. The Company creates and delivers advancements in early intervention orthopedic care. It partners with physicians and develops minimally invasive products. It focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair and bone preserving joint technologies. Its product categories include joint pain management therapies, orthopedic joint preservation and restoration care, and other. The joint pain management therapies offer injectable viscosupplement products that provide pain relief from osteoarthritis conditions and its products include MONOVISC, ORTHOVISC, CINGAL and HYVISC. The Company's orthopedic joint preservation and restoration care products include HYALOFAST and TACTOSET. It also offers a line of surgical implant and instrumentation solutions that are used by surgeons to repair and reconstruct damaged ligaments and tendons due to sports injuries, trauma and disease.

Directors
Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated June 6, 2018
Public Since May 16, 1985
No. of Shareholders: 116
No. of Employees: 154
Sector Healthcare
Industry Pharmaceuticals
Index Nasdaq Composite , S&P 600 Small Cap , S&P Composite 1500 ,
Exchange NASDAQ Global Select Market
Shares in Issue 14,214,516
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ANIK Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ANIK
Upcoming Events for ANIK
Frequently Asked Questions for Anika Therapeutics Inc
What is the Anika Therapeutics Inc share price?

As of 22/01/21, shares in Anika Therapeutics Inc are trading at $38.96, giving the company a market capitalisation of £406.1m. This share price information is delayed by 15 minutes.

How has the Anika Therapeutics Inc share price performed this year?

Shares in Anika Therapeutics Inc are currently trading at $38.96 and the price has moved by -14.18% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Anika Therapeutics Inc price has moved by -25.9% over the past year.

What are the analyst and broker recommendations for Anika Therapeutics Inc?

Of the analysts with advisory recommendations for Anika Therapeutics Inc, there are there are currently 2 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Anika Therapeutics Inc is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Anika Therapeutics Inc next release its financial results?

Anika Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Anika Therapeutics Inc dividend yield?

Anika Therapeutics Inc does not currently pay a dividend.

Does Anika Therapeutics Inc pay a dividend?

Anika Therapeutics Inc does not currently pay a dividend.

When does Anika Therapeutics Inc next pay dividends?

Anika Therapeutics Inc does not currently pay a dividend.

How do I buy Anika Therapeutics Inc shares?

To buy shares in Anika Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Anika Therapeutics Inc?

Shares in Anika Therapeutics Inc are currently trading at $38.96, giving the company a market capitalisation of £406.1m.

Where are Anika Therapeutics Inc shares listed? Where are Anika Therapeutics Inc shares listed?

Here are the trading details for Anika Therapeutics Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: ANIK
What kind of share is Anika Therapeutics Inc?

Based on an overall assessment of its quality, value and momentum, Anika Therapeutics Inc is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Anika Therapeutics Inc share price forecast 2021?

Shares in Anika Therapeutics Inc are currently priced at $38.96. At that level they are trading at 32.55% discount to the analyst consensus target price of 0.00.

Analysts covering Anika Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.51 for the next financial year.

How can I tell whether the Anika Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Anika Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been -7.51%. At the current price of $38.96, shares in Anika Therapeutics Inc are trading at 8.34% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Anika Therapeutics Inc PE Ratio?

The Anika Therapeutics Inc PE ratio based on its reported earnings over the past 12 months is 57.84. The shares are currently trading at $38.96.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Anika Therapeutics Inc?

Anika Therapeutics Inc's management team is headed by:

Joseph Bower - CHM
Raymond Land - IND
Jeffery Thompson - IND
Glenn Larsen - IND
Thomas Finnerty - EVP
Cheryl Blanchard - PRE
David Colleran - EVP
James Loerop - EVP
Michael Levitz - CFO
John Henneman - IND
Stephen Richard - IND
Who are the major shareholders of Anika Therapeutics Inc?

Here are the top five shareholders of Anika Therapeutics Inc based on the size of their shareholding:

BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 13.78% (1.96m shares)
Kayne Anderson Rudnick Investment Management, LLC Investment Advisor
Percentage owned: 10.49% (1.49m shares)
Columbia Wanger Asset Management, LLC Investment Advisor
Percentage owned: 6.56% (933k shares)
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund
Percentage owned: 6.48% (922k shares)
iShares Core S&P Small-Cap ETF Mutual Fund
Percentage owned: 6.46% (918k shares)
Similar to ANIK
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.